

Protein Mechanics
1st Seminar
Discovery and Study of Metabolic Pathway


Lanosterol Biosynthesis

Kalaitzaki Eirini-Eleni
Mpatsolaki Foteini
Papangeli Olga-Maria

April 2024



ΠΑΝΕΠΙΣΤΗΜΙΟ ΚΡΗΤΗΣ
UNIVERSITY OF CRETE




Contents

- Introduction
- Steroid Biosynthesis
- Lanosterol Metabolic Pathway
- Alternative Pathway
- Why Lanosterol Synthase?
- The Origin of Lanosterol Synthase
- *Saccharomyces cerevisiae*: The best studied eukaryote
- Nucleotide Sequence of the *SceERG7* Gene
- Amino Acid Sequence of the *SceERG7* Gene
- Characteristics of the fungal Lanosterol Synthase (*SceERG7*)
- References


Introduction

Lanosterol was first isolated from sheep's wool in 1930 by German researchers A. Windhaus and R. Tschesche



In **photosynthetic organisms** (plants, algae) the role of lanosterol is taken by cycloartenol, a **cyclopropane triterpenoid**.


Cycloartenol is the precursor of all sterols in plants and is also derived from squalene oxide.



Introduction


•**Steroids** are triterpenoid derivatives that contain the tetracyclic ring system of **lanosterol** but lack the three methyl groups in C-4 and C-14.

“the core structure from which all others are derived by biological modification”
(Merck Index)



Introduction

Cholesterol
derived steroids...




Introduction

- **Lanosterol & Cataract Treatment**


What's cataract?

Crystalline proteins form a strict macro-structure responsible for: i) less transparency and ii) refractive index

Lanosterol synthase (LSS) is expressed in the eye lens!



PDB entry: 2G98



“Aggregation is an intrinsic property of mutant crystallines.”(Zhao et al. 2015)

Introduction



W581R, G588S



Loss of LSS cyclase activity

h, Effects of DMSO, cholesterol or lanosterol on α A-crystallin(Y118D) aggregates in human lens progenitor cells by serial live-cell imaging. Progression of crystallin aggregation dissolution by lanosterol can be observed, as evidenced by decreased green fluorescence following the time-course.

h




Conclusion:

- Lanosterol, not cholesterol, and
 - WT-LSS
- can decrease preformed crystalline aggregates



Introduction

- Dogs treated with lanosterol showed increased lens clarity




- 2022:** Effect of lanosterol concentration in lens opacification and proteins in cynomolgus monkeys

- First in vivo model on primates!**
- Thermogel injection

CONTROL	NATURAL CORTICOID CATARACT	NUCLEAR CATARACT
		

(E)



Introduction

Increased LDL cholesterol levels are associated with coronary heart disease (CHD)



Development of cholesterol biosynthesis **inhibitors**



Inhibition of rate limiting step of the conversion of lanosterol to cholesterol (catalyzed by **P-450DM**)



Lanosterol analogs as inhibitors

Competitive inhibitor of HMGR (hypercholesterolemia)

Mevacor® 40 mg (Lovastatin)


Manuf. for: Merck Sharp & Dohme Corp., a subsidiary of
MERCK & CO., INC.
Whitehouse Station, NJ 08889, USA
By:
Mylan Pharmaceuticals Inc.
Morgantown, WV 26505, USA
Lovastatin (active ingred.) Made in India
Formulated in USA

Each tablet contains 40 mg of lovastatin.


60 Tablets

Lot:

Exp.:



Introduction



Lanosterol analog 9:



- Binds more tightly to P-450DM compared to 24,25-dihydrolanosterol (6) which is one of the natural substrates
- Competitive inhibitor
- Endogenous suppressor of HMGR





Inhibitors

- **Type 1:** 25a, 25b, 26, similar structure to natural intermediates (i.e 9)
- **Type 2:** Aminolanosterols
- **Type 3:** Ketone or oxime analogs of lanosterol (C-15)

Introduction

Table 1 Summary of the Biochemical Evaluation of Selected Potential Dual-Action Inhibitors of Cholesterol Biosynthesis

	Inhibitor	IC ₅₀ (μM)				Reference
		P-450DM		HMGR		
		<i>in vitro</i> ^a	CHO	CHO	AR45	
T Y P E 1	 24	>100	5.0	1.0	>20	31, 46
	 9 R=CHO	NA ^b	1.9	3.0	2.0	16, 32
	25a R=CH(OH)CH ₃ (less polar diastereomer)	0.33	0.3	3.0	>20	7, 39
	25b R=CH(OH)CH ₃ (more polar diastereomer)	1.6	0.3	1.5	>20	7, 39
	26 R=C(CH ₃)O	9.1	2.7	1.0	>20	7, 39
	27 R=NOH	8.9	4.5	1.0	2.0	40
	28 R=NOCH ₃	100	>20	10	>20	40

T Y P E 2	 29	4.0	>20	1.5	>20	
	 30	1.5	0.15	6.0	>20	
	 31	60	1.0	2.0	5.0	
T Y P E 3	 32 R=O	7.1	1.0	0.5	1.8	40
	33 R=NOH	3.0	2.0	0.6	1.5	40
	34 R=NOCH ₃	77	>20	15	>20	40
	35 R=NOBn	100	>20	15	NA	40

Experiments carried out using rat liver microsomal preparations.


IC₅₀ value is not available.

See Reference 16 for details of inhibition of P-450DM by compound 9.





squalene

squalene
epoxidase




enzymatic
cyclization



steroid numbering

Squalene




C00751

Squalene monooxygenase

Alternative squalene epoxidase


(S)—Squalene—2,3—epoxide



C01054


Lanosterol synthase

Lanosterol



C01724

Squalene



C00751



- Formula: $C_{30}H_{50}$
- Alternative names: spinacene, supraene
- KEGG entry: C00751
- CAS number: 111-02-4
- Price per 1 gram: €301*



*As analytical standard from Sigma Aldrich

Squalene monooxygenase

- EC number: 1.14.14.17
1. Oxidoreductases
1.14 Acting on paired donors with incorporations or reduction of molecular O₂
1.14.14 With reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen into the other donor
1.14.14.17 Squalene monooxygenase

Alternative squalene oxidase


- EC number: 1.14.19.-
1. Oxidoreductases
1.14 Acting on paired donors with incorporations or reduction of molecular O₂
1.14.19 With oxidation of a pair of donors resulting in the reduction of O₂ to two molecules of water

Reaction catalyzed by squalene monooxygenase:

Squalene + reduced NADPH-hemoprotein reductase + O₂ → oxidized NADPH + H₂O

Cofactor: NADPH + FAD

(3S)-2,3-epoxy-2,3-dihydrosqualene +




Reaction catalyzed by alternative squalene oxidase:

Squalene + 2 Ferrocyanochrome b5 + O₂ + 2H → (S)-2,3-epoxysqualene + 2 Ferricytochrome b5 + H₂O


Cofactor: Fe*

*Ferrocyanochrome b5 pubchem substance SID: 4245

Ferricytochrome b5 pubchem substance SID: 4242




Squalene



Squalene monooxygenase


Alternative squalene epoxidase

(S)—Squalene—2,3—epoxide




Lanosterol synthase

Lanosterol



(S)-Squalene-2,3-epoxide



C01054

- Formula: $C_{30}H_{50}O$
- Alternative names: (S)-2,3-epoxisqualene, Squalene-2,3-oxide, 2,3-oxidosqualene, (3S)-2,3-epoxy-2,3-dihydrosqualene
- CAS number: 54910-48-4
- KEGG entry: C01054

Lanosterol Synthase

- EC number: 5.4.99.7
 - 5. Isomerases
 - 5.4 Intramolecular transferases
 - 5.4.99 Transferring other groups
 - 5.4.99.7 Lanosterol


synthase

- Cofactor: None
- It catalyzes the cyclization of (S)-Squalene-2,3-epoxide

Reaction:




Squalene



Squalene monooxygenase


Alternative squalene epoxidase

(S)—Squalene—2,3—epoxide




Lanosterol synthase

Lanosterol




Lanosterol



- Formula: C₃₀H₅₀O
- Alternative names: 4,4',14-alpha-trimethyl-5alpha-cholesta-8,24-dien-3beta-ol
- KEGG entry: C01724
- CAS number: 79-63-0
- Price per 5 mg: €821*

*>=93%, powder. From Sigma Aldrich

Alternative Pathway: Lanosteryl acetate




- Formula: C₃₂H₅₂O₂
- Alternative names: Lanosta-8,24-dien-3β-ol, acetate/ Lanosta-8,24-dien-3β-yl acetate/ Lanosterol acetate/ Lanosteryl acetate/ 3β-Acetoxylanosta-8,24-diene


- CAS number: 2671-68-3
- Molecular weight: 468.7541
- Price per 5 mg: €464.48*

* 95.00% Lanosteryl acetate from ChemicalBook


Why Lanosterol Synthase?



The Origin of Lanosterol Synthase



Saccharomyces cerevisiae: The best studied eukaryote



brewer's yeast



baker's yeast



Lanosterol synthase
is a preferred target
of antifungal drugs

- ✓ It has been extensively studied → Model unicellular organism
- ✓ Genetic manipulation → Easy overexpression or deletion of genes
- ✓ High expression levels
- ✓ Stable and scalable → cost-effectiveness
- ✓ Reduced risk of contamination

Nucleotide Sequence of the *SceERG7* Gene

ATGACAGAATTTTATTCTGACACAATCGGTCTACCAAAGACAGATCCACGTCTTTGGAGACTGAGAACTGATGAGCTAGGCCGAGAAAGCTGGGAATATTTAACCCCTCAGCAAGCCGCA
AACGACCCACCATCCACTTTCACGCAGTGGCTTCTTCAAGATCCCAAATTTCTCAACCTCATCCAGAAAGAAATAAGCATTACCCAGATTTTTTCAGCCTTCGATGCGTGTGATAATGGT
GCATCTTTTTTCAAACCTGCTTCAAGAGCCTGACTCAGGTATTTTTCCGTGTCAATATAAAGGACCCATGTTTCATGACAATCGGTTACGTAGCCGTAAACTATATCGCCGGTATTGAAATT
CCTGAGCATGAGAGAATAGAATTAATTAGATACATCGTCAATACAGCACATCCGGTTGATGGTGGCTGGGGTCTACATTCTGTTGACAAATCCACCGTGTGTTGGTACAGTATTGAACTAT
GTAATCTTACGTTTATTGGGTCTACCCAAGGACCACCCGGTTTGCGCCAAGGCAAGAAGCACATTGTTAAGGTTAGGCGGTGCTATTGGATCCCCTCACTGGGGAAAAATTTGGCTAAGT
GCACTAAACTTGTATAAATGGGAAGGTGTGAACCCTGCCCTCCTGAAACTTGGTTACTTCCATATTTCACTGCCCATGCATCCGGGGAGATGGTGGGTTTCATACTAGAGGTGTTTACATT
CCGGTCAGTTACCTGTCATTGGTCAAATTTTCTTGCCCAATGACTCCTCTTCTTGAAGAACTGAGGAATGAAATTTACACTAAACCGTTTGACAAGATTAACCTTCTCCAAGAACAGGAAT
ACCGTATGTGGAGTAGACCTATATTACCCCATTTCTACTACTTTGAATATTGCGAACAGCCTTGTAGTATTTTACGAAAAATACCTAAGAAACCGGTTCAATTTACTCTCTATCCAAGAAG
AAGGTTTATGATCTAATCAAAACGGAGTTACAGAATACTGATTCCTTGTGTATAGCACCTGTTAACCAGGCGTTTTGCGCACTTGTCACCTTATTGAAGAAGGGGTAGACTCGGAAGCG
TTCCAGCGTCTCCAATATAGGTTCAAGGATGCATTGTTCCATGGTCCACAGGGTATGACCATTATGGGAACAAATGGTGTGCAAACCTGGGATTTGTGCGTTTGCCATTCAATACTTTTTC
GTCGCAGGCCTCGCAGAAAGACCTGAATTCATAACACAATTGTCTCTGCCTATAAATTCTTGTGTGCATGCTCAATTTGACACCGAGTGCGTTCCAGGTAGTTATAGGGATAAGAGAAAG
GGGGCTTGGGGCTTCTCAACAAAAACACAGGGCTATACAGTGGCAGATTGCACTGCAGAAGCAATTAAAGCCATCATCATGGTGAAAACTCTCCCGTCTTTAGTGAAGTACACCATATG
ATTAGCAGTGAACGTTTATTTGAAGGCATTGATGTGTTATTGAACCTACAAAACATCGGATCTTTTGAATATGGTTCCTTTGCAACCTATGAAAAATCAAGGCCCCACTAGCAATGGAA
ACCTTGAATCCTGCTGAAGTTTTTGGTAACATAATGGTAGAATACCCATACGTGGAATGTACTGATTCATCCGTTCTGGGGTTGACATATTTTCACAAGTACTTCGACTATAGGAAAGAG
GAAATACGTACACGCATCAGAATCGCCATCGAATTCATAAAAAAATCTCAATTACCAGATGGAAGTTGGTATGGAAGCTGGGGTATTTGTTTTACATATGCCGGTATGTTTGCATTGGAG
GCATTACACACCGTGGGGGAGACCTATGAGAATTCCTCAACGGTAAGAAAAGGTTGCGACTTCTTGGTCAGTAAACAGATGAAGGATGGCGGTTGGGGGAATCAATGAAGTCCAGTGAA
TTACATAGTTATGTGGATAGTGAAAAATCGCTAGTCGTTCAAACCGCATGGGCGCTAATTGCACTTCTTTTCGCTGAATATCCTAATAAAGAAGTCATCGACCGCGGTATTGACCTTTTA
AAAAATAGACAAGAAGAATCCGGGGAATGGAAATTTGAAAGTGTAGAAGGTGTTTTCAACCACTCTTGTGCAATTGAATACCCAAGTTATCGATTCTTATTCCTATTAAGGCATTAGGT
ATGTACAGCAGGGCATATGAAACACATACGCTT**TAA**

2196 nucleotides (bp)



Amino Acid Sequence of the *SceERG7* Gene

MTEFYSDTIGLPKTDPRWLRLRTDELGRESWEYLTPQQAANDPPSTFTQWLLQDPKFPQP
HPERNKHSPDFSAFDACHNGASFFKLLQEPDSGIFPCQYKGPMFMTIGYVAVNYIAGIEI
PEHERIELIRYIVNTAHPVDGGWGLHSVDKSTVFGTVLNYVILRLLGLPKDHPVCAKARS
TLLRLGGAIGSPHWGKIWLSALNLYKWEGVNPAPPETWLLPYSLPMHPGRWWVHTRGVYI
PVSYLSLVKFSCPMTPLLEELRNEIYTKPFDKINFSKNRNTVCGVDLYYPHSTTLNIANS
LVVFYEKYLNRNRFIYSLSKKKVYDLIKTELQNTDSLCAIPVNQAFCALVTLIEEGVDSEA
FQRLQYRFKDALFHGPQGMTIMGTNGVQTDCAFAIQYFFVAGLAERPEFYNTIVSAYKF
LCHAQFDTECVPGSYRDKRKGAWGFSTKTQGYTVADCTAEAIKAIIMVKNSPVFSEVHHM
ISSERLFEGIDVLLNLQNIGSFEYGSFATYEKIKAPLAMETLNPAEVFGNIMVEYPYVEC
TDSSVLGLTYFHKYFDYRKEEIRTRIRIAIEFIKKSQLPDGSWYGSWGICFTYAGMFALE
ALHTVGETYENSSTVRKGCDFLVSKQMKDGGWGESMKSSSELHSYVDSEKSLVVQTAWALI
ALLFAEYPNKEVIDRGIDLLKNRQEESGEWKFESEGVFNHSCAIEYPSYRFLFPIKALG
MYSRAYETHTL

731 amino acids



: Characteristics of the fungal Lanosterol Synthase (*SceERG7*)

Stable protein

MOLECULAR WEIGHT	pI (Theoretical)	INSTABILITY INDEX (II)	EXTINCTION COEFFICIENT (M ⁻¹ cm ⁻¹ at 280 nm)		ABSORBANCE 0.1%(=1 g L ⁻¹ , OPTICAL DENSITY)	
			With cystines:	Without cystines:	With cystines:	Without cystines:
83460.42 g mol ⁻¹	6.16	39.76	153975	153100	1.845	1.834

$E = \#(Tyr) \times Ext(Tyr) + \#(Trp) \times Ext(Trp) + \#(Cystine) \times Ext(Cystine),$

Where: $\#(Tyr)=40$, $Ext(Tyr)=1490$, $\#(Trp)=17$, $Ext(Trp)=5500$, $\#(Cystine)=7$, $Ext(Cystine)=125$

$Absorb = E \div Molecular\ weight$
Where: Molecular weight= 83460.42 g mol⁻¹



SOLUPROT

Protein	Solubility
sce:YHR072W	0.447

The Lanosterol synthase song

1

OS-Cyclase, OS-Cyclase, a great
enzyme are you
OS-Cyclase, OS-Cyclase, the sterol
pathway needs you
You take open squalene oxide, And
quickly form four rings from it
OS-Cyclase, OS-Cyclase, you shape
the steroid backbone.

2

OS-Cyclase, OS-Cyclase, in
eukaryotes you spread out
OS-Cyclase, OS-Cyclase, bacteria
cells do not lodge you
In fungi and animals you form
Just triterpene lanosterol,
In plants your creativity bursts
into plenty of compounds.

3

Lord of the Rings, Lord of the Rings,
your mechanism is magic
Your action starts from (an)
aspartate, that protonates the
substrate
The target is its epoxide,
Which opens forming alcohol group,
From then no one, from then no one,
can stop cyclizing process.

4

Electron cloud of double bond starts
soon to be excited
And as a hungry dog to a bone it
throws itself on C-2
Forming the first of the four rings,
Leaving a new plus charge behind,
A thrill knocks on the door of all the
other double bond clouds.

...

References

1. Dewick, P. M.; Netlibrary, I. *Medicinal Natural Products : A Biosynthetic Approach*; Wiley: Chichester, West Sussex, England ; New York, Ny, Usa, 2002.
2. Du, Y.; Fu, X.; Chu, Y.; Wu, P.; Liu, Y.; Ma, L.; Tian, H.; Zhu, B. Biosynthesis and the Roles of Plant Sterols in Development and Stress Responses. *International Journal of Molecular Sciences* **2022**, 23 (4), 2332. <https://doi.org/10.3390/ijms23042332>.
3. Zhao, L.; Chen, X.-J.; Zhu, J.; Xi, Y.-B.; Yang, X.; Hu, L.-D.; Ouyang, H.; Patel, S. H.; Jin, X.; Lin, D.; Wu, F.; Flagg, K.; Cai, H.; Li, G.; Cao, G.; Lin, Y.; Chen, D.; Wen, C.; Chung, C.; Wang, Y. Lanosterol Reverses Protein Aggregation in Cataracts. *Nature* **2015**, 523 (7562), 607–611. <https://doi.org/10.1038/nature14650>.
4. Zhang, K.-K.; He, W.-W.; Du, Y.; Zhou, Y.; Wu, X.; Zhu, J.; Zhu, X.-J.; Kang, Z.; Lu, Y. Inhibitory Effect of Lanosterol on Cataractous Lens of Cynomolgus Monkeys Using a Subconjunctival Drug Release System. *Precision Clinical Medicine* **2022**, 5 (3). <https://doi.org/10.1093/pcmedi/pbac021>.
5. Bank, R. P. D. 3D View: 2G98. *human gamma-D-crystallin*
6. Frye, L. L.; Leonard, D. A. Lanosterol Analogs: Dual-Action Inhibitors of Cholesterol Biosynthesis. *Critical Reviews in Biochemistry and Molecular Biology* **1999**, 34 (2), 123–140. <https://doi.org/10.1080/10409239991209246>.

References

7. *KEGG - Table of Contents*. Genome.jp. <https://www.genome.jp/kegg/kegg2.html> (accessed 2024-04-02)
8. BRENDA Enzyme Database. Brenda-enzymes.org. <https://www.brenda-enzymes.org/index.php> (accessed 2024-04-02).
9. UniProt. Uniprot.org. <https://www.uniprot.org/> (accessed 2024-04-02).
10. National Center for Biotechnology Information. Nih.gov. <https://www.ncbi.nlm.nih.gov/> (accessed 2024-04-02).
11. Data, P. RCSB PDB: Homepage. Rcsb.org. <https://www.rcsb.org/> (accessed 2024-04-02).
12. PubChem. PubChem. @pubchem. <https://pubchem.ncbi.nlm.nih.gov/> (accessed 2024-04-02).
13. Finnigan, W. RetroBioCat. Retrobiocat.com. <https://retrobiocat.com/> (accessed 2024-04-02).
14. Corey, E. J.; Matsuda, S. P. T.; Bartel, B. Molecular cloning, characterization, and overexpression of ERG7, the *Saccharomyces cerevisiae* gene encoding lanosterol synthase. *Proceedings of the National Academy of Sciences of the United States of America* **1994**, 91 (6), 2211–2215. DOI: <https://doi.org/10.1073/pnas.91.6.2211>.
15. Kürten, C.; Uhlén, M.; Syrén, P. Overexpression of functional human oxidosqualene cyclase in *Escherichia coli*. *Protein Expression and Purification* **2015**, 115, 46–53. DOI: <https://doi.org/10.1016/j.pep.2015.04.015>.
16. Baker, C. H.; Matsuda, S. P. T.; Liu; Corey, E. J. Molecular-Cloning of the Human Gene Encoding Lanosterol Synthase from a Liver cDNA Library. *Biochemical and Biophysical Research Communications* **1995**, 213 (1), 154–160. <https://doi.org/10.1006/bbrc.1995.2110>.
17. Shang, C.; Shi, L.; Ren, A.; Qin, L.; Zhao, M. Molecular Cloning, Characterization, and Differential Expression of a Lanosterol Synthase Gene from *Ganoderma lucidum*. *Bioscience, Biotechnology, and Biochemistry* **2010**, 74 (5), 974–978. DOI: <https://doi.org/10.1271/bbb.90833>.

References

- 18.**Huang, Z.-R.; Lin, Y.-K.; Fang, J.-Y. Biological and Pharmacological Activities of Squalene and Related Compounds: Potential Uses in Cosmetic Dermatology. *Molecules* **2009**, *14* (1), 540–554. DOI: <https://doi.org/10.3390/molecules14010540>.
- 19.** Myko San. *Health-Benefits-of-Ganoderma-Lucidum-Medicinal-Mushrooms - Myko San*. Myko San. <https://mykosan.com/medicinal-mushrooms-traditions-of-the-east/health-benefits-of-ganoderma-lucidum-medicinal-mushrooms/>. (accessed 2024-04-02)
- 20.**Gianni Balliano. Song: Oxidosqualene (OS) Cyclase—Lanosterol Synthase (to the Tune of “Oh Christmas Tree”). *Biochemistry and Molecular Biology Education* **2021**, *49* (2), 301–302. DOI: <https://doi.org/10.1002/bmb.21490>.
- 21.**Kolesnikova, M. D.; Xiong, Q.; Lodeiro, S.; Ling, H.; Matsuda, S. P. T. Lanosterol biosynthesis in plants. *Archives of Biochemistry and Biophysics (Print)* **2006**, *447* (1), 87–95. DOI: <https://doi.org/10.1016/j.abb.2005.12.010>.
- 22.**Woodward, A. W.; Bartel, B. Biology in Bloom: A Primer on the Arabidopsis thaliana Model System. *Genetics* **2018**, *208* (4), 1337–1349. DOI: <https://doi.org/10.1534/genetics.118.300755>.
- 23.***saccharomyces cerevisiae*. https://pdfprof.com/PDF_Image.php?id=68879&t=18.
- 24.**Parapouli, M.; Vasileiadis, A.; Afendra, A. S.; Hatziloukas, E. *Saccharomyces cerevisiae* and its industrial applications. *AIMS Microbiology* **2020**, *6* (1), 1–32. <https://doi.org/10.3934/microbiol.2020001>.
- 25.**KEGG T00005: YHR072W. <https://www.kegg.jp/entry/sce:YHR072W>. (accessed 2024-04-01)
- 26.**Expasy - ProtParam tool. <https://web.expasy.org/protparam/>.
- 27.**Laboratories, J. H. L. SoluProt 1.0 – Prediction of soluble protein expression in Escherichia coli. <https://loschmidt.chemi.muni.cz/soluprot/>. (accessed 2024-04-03)